Header Logo

Connection

TITO R MENDOZA to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications TITO R MENDOZA has written about Antibodies, Monoclonal, Humanized.
TITO R MENDOZA
Connection Strength
0.098
Antibodies, Monoclonal, Humanized
  1. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.
    View in: PubMed
    Score: 0.098
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.